AR108800A1 - Purificación de anticuerpos multiespecíficos - Google Patents

Purificación de anticuerpos multiespecíficos

Info

Publication number
AR108800A1
AR108800A1 ARP170101667A ARP170101667A AR108800A1 AR 108800 A1 AR108800 A1 AR 108800A1 AR P170101667 A ARP170101667 A AR P170101667A AR P170101667 A ARP170101667 A AR P170101667A AR 108800 A1 AR108800 A1 AR 108800A1
Authority
AR
Argentina
Prior art keywords
purification
specific antibodies
mixed mode
chromatography
specific impurities
Prior art date
Application number
ARP170101667A
Other languages
English (en)
Inventor
Yinges Yigzaw
Kimberly Kaleas
Agathe Bialas
Steffen Willmann
Wolfgang Koehnlein
Susanne Konrad
Bernard Sallier
Eva Rosenberg
Glen Giese
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR108800A1 publication Critical patent/AR108800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona métodos para purificar anticuerpos multiespecíficos. Los métodos comprenden las etapas secuenciales de realizar una cromatografía de captura, una primera cromatografía de modo mixto y una segunda cromatografía de modo mixto. En algunos aspectos, proporciona composiciones de anticuerpos multiespecíficos, en donde dichas composiciones tienen niveles reducidos de una o más impurezas específicas del producto y/o impurezas específicas del proceso.
ARP170101667A 2016-06-17 2017-06-16 Purificación de anticuerpos multiespecíficos AR108800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351908P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
AR108800A1 true AR108800A1 (es) 2018-09-26

Family

ID=59593150

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101667A AR108800A1 (es) 2016-06-17 2017-06-16 Purificación de anticuerpos multiespecíficos

Country Status (14)

Country Link
US (1) US20190256556A1 (es)
EP (1) EP3472177A2 (es)
JP (2) JP2019521986A (es)
KR (2) KR20190039929A (es)
CN (1) CN109563124A (es)
AR (1) AR108800A1 (es)
AU (1) AU2017286676A1 (es)
BR (1) BR112018075516A2 (es)
CA (1) CA3026518A1 (es)
IL (1) IL263690B2 (es)
MX (1) MX2018015173A (es)
SG (1) SG11201810777WA (es)
TW (1) TWI798179B (es)
WO (1) WO2017218977A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
EP3676280A1 (en) * 2017-08-30 2020-07-08 Fresenius Kabi Deutschland GmbH Method for purifying anti-il-6 receptor antibodies
CN111491951B (zh) * 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
WO2019149693A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process and platform
US20210040146A1 (en) * 2018-01-30 2021-02-11 Exothera S.A. Protein purification process
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2020160118A1 (en) 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
CA3137116A1 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
WO2020258704A1 (zh) * 2019-06-28 2020-12-30 信达生物制药(苏州)有限公司 无缝连续流层析方法
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
KR20220092958A (ko) * 2019-11-07 2022-07-04 암젠 인크 산물-관련 불순물을 제거하기 위한 양이온 교환 크로마토그래피 동안의 고염 세척
JP2023510382A (ja) * 2020-01-15 2023-03-13 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質製造プロセスから不純物を減少させる方法
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
CN115066258A (zh) * 2020-02-28 2022-09-16 上海药明生物技术有限公司 双特异性抗体的纯化
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
CN114539416A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
KR20230154043A (ko) * 2021-03-09 2023-11-07 제이씨알 파마 가부시키가이샤 항체-리소좀 효소 융합 단백질의 제조 방법
US20240191179A1 (en) * 2021-04-23 2024-06-13 Kyowa Kirin Co., Ltd. Method for suppressing production of degradation products
WO2022222949A1 (zh) * 2021-04-23 2022-10-27 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法
WO2022272119A2 (en) * 2021-06-25 2022-12-29 The Board Of Trustees Of The University Of Illinois Synthetic toolkit for plant transformation
KR20230057280A (ko) * 2021-10-19 2023-04-28 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 정제방법
WO2024076990A1 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2002245142B2 (en) 2000-12-14 2007-07-05 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
AU2005216847B2 (en) * 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
JP5719354B2 (ja) 2009-05-27 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三重又は四重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
BR112012029904A2 (pt) 2010-05-25 2017-08-08 Genentech Inc métodos de purificação de polipeptídeos
US9422329B2 (en) * 2010-11-05 2016-08-23 Hoffmann-La Roche Inc. Optimized method for antibody capturing by mixed mode chromatography
ES2682081T3 (es) 2011-10-11 2018-09-18 F. Hoffmann-La Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
EP3495387B1 (en) 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
EP3036253B1 (en) * 2013-08-19 2020-09-23 F. Hoffmann-La Roche AG Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
WO2015070068A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
WO2015135884A1 (en) * 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
CA3026518A1 (en) 2017-12-21
KR20230113662A (ko) 2023-07-31
WO2017218977A2 (en) 2017-12-21
TWI798179B (zh) 2023-04-11
WO2017218977A3 (en) 2018-01-18
IL263690A (en) 2019-01-31
SG11201810777WA (en) 2018-12-28
AU2017286676A1 (en) 2018-12-13
US20190256556A1 (en) 2019-08-22
CN109563124A (zh) 2019-04-02
TW201803902A (zh) 2018-02-01
MX2018015173A (es) 2019-07-04
EP3472177A2 (en) 2019-04-24
AU2017286676A8 (en) 2018-12-20
KR20190039929A (ko) 2019-04-16
JP2022166004A (ja) 2022-11-01
WO2017218977A8 (en) 2019-03-28
IL263690B1 (en) 2023-01-01
JP2019521986A (ja) 2019-08-08
IL263690B2 (en) 2023-05-01
BR112018075516A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
GT201700136A (es) Formas sólidas de un inhibidor ask 1
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CU24498B1 (es) Anticuerpos de factor xi
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790630A1 (ru) Способы получения рибозидов
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
DK3355329T3 (da) Metode til fremstilling af lithium-ion-kondensator og kondensator som opnås med den nævnte metode
DK3313997T3 (da) Fremgangsmåde til fremstilling af mølferomoner i gær
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
CO2018006667A2 (es) Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
DK3528838T3 (da) Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis
EA201890572A1 (ru) Биофармацевтические композиции
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas